Depot neuroleptics, schizophrenia and the role of the nurse: Is practice evidence based? A review of the literature

Journal of Advanced Nursing

Volumn 30, Issue 6, 1999, Pages 1255-1262

  Marland, Glenn R ^a   Sharkey, Val ^b  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b Crichton Royal Hospital   (United Kingdom)

Author keywords

Depots; Empowerment; Evidence; Neuroleptics; Nursing; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

COMMUNITY HEALTH NURSING; DELAYED RELEASE FORMULATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; HUMAN; KNOWLEDGE; METHODOLOGY; NURSING; NURSING RESEARCH; PATIENT ADVOCACY; PATIENT COMPLIANCE; PSYCHIATRIC NURSING; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; WORK;

ANTIPSYCHOTIC AGENTS; COMMUNITY HEALTH NURSING; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; JOB DESCRIPTION; KNOWLEDGE; NURSING RESEARCH; PATIENT ADVOCACY; PATIENT COMPLIANCE; PSYCHIATRIC NURSING; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033258088     PISSN: 03092402     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2648.1999.01227.x     Document Type: Article

References (64)

1. Adams C. & Eisenbruch M. (1997) (Date of most recent substantive amendment: 27 August). Depot vs oral fluphenazine for schizophrenia (Cochrane Review). In The Cochrane Library, Issue 4, 1998. Update Software, Oxford.
2. Brown C.S., Wright R.G. & Christenson D.B. (1987) Association between type of medication, instruction, and patient's knowledge, side effects, and compliance. Hospital Community Psychiatry 38(1), 55-60.
3. Brown W.S., Laughren T., Chisholm E. & Willisma B.W. (1982) Low serum neuroleptic levels predict relapse in schizophrenic patients. Archives of General Psychiatry 39, 998-1000.
4. Breggin P. (1993) Toxic Psychiatry. Harper Collins, London.
5. Campbell P. (1996) Challenging loss of power. In Speaking our Minds. An Anthology (Reid J. & Reynolds J. eds), MacMillan Press, London, pp. 56-62.
6. Cassino T., Appellman L., Heiman J., Shupe J. & Sklebar H. (1987) Invitation to compliance: the prolixin brunch. Journal of Psychosocial Nursing and Mental Health Services 25(10), 15.
7. Chewning B. & Sleath B. (1996) Medication decision-making and management: a client-centered model. Social Science & Medicine 42(3), 389-398.
8. Davis J. & Andriukatis S. (1986) The natural course of schizophrenia and effective maintenance drug therapy. Journal of Clinical Psychopharmacology 6(1 Suppl.), 2-10.
9. Day J., Henderson B. & Butterworth T. (1995) Shaping up the depot. Nursing Times 91(44), 51-54.
10. Dencker J.S. & Axelsson R. (1996) Optimising the use of depot antipsychotics. Central Nervous Systems Drugs 6(5), 367-381.
11. Department of Health and Ministerial Review (1994) Working in Partnership. A Collaborative Approach to Care. Her Majesty's Stationery Office, London.
12. Department of Health: Royal College of Nursing (1994) Good Practice in the Administration of Depot Neuroleptics: A Guidance Document for Mental Health and Practice Nurses. DoH/ RCN, London.
13. Eckman T.A. & Liberman R.P. (1991) A large-scale field test of a medication management skills training program for people with schizophrenia. Psychosocial Rehabilitation Journal 3, 31-35.
14. Favrod J. (1993) Taking back control... giving patients information about their drug regimes improves compliance. Nursing Times 89(34 Mental Health), 68-70.
15. Fortinash K. & Holoday-Worret P. (1996) Psychiatric-Mental Health Nursing. Mosby, London.
16. Gerlach J. & Larsen E. (1996) Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatrica Scandinavica 93(5), 381-388.
17. Gray R., Gournay K. & Taylor D. (1997) New drug treatments for schizophrenia: implications for mental health nursing. Mental Health Practice 1(1), 20-23.
18. Green J.H. (1988) Frequent rehospitalisations and compliance with treatment. Hospital and Community Psychiatry 39, 963-966.
19. Haynes R.B., Taylor D.W. & Sackett D.L. (1979) Compliance in Health Care. The John Hopkins Press, London.
20. Hogarty G.E., Schooler N.R., Ulrich R., Mussare F. & Ferro P. (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate in the continuation therapy of schizophrenia. Archives of General Psychiatry 36, 1283-1294.
21. th edn. W.H. Freeman and Company, New York.
22. Kane J. (1985) Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology 5 (Suppl. 3), 22-27.
23. Kane J., Rifkin A., Quitkin F. et al. (1979) Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Research 1, 341-348.
24. Kane J.M., Rifkin A., Woerner M. et al. (1983) Low dose neuroleptic treatment of outpatient schizophrenics 1. Preliminary results for relapse rates. Archives of General Psychiatry 40, 893-896.
25. Kelly J. (1995) Making sense of drug compliance by patients. Nursing Times 91(40), 40-41.
26. Kemp R. & David A. (1996) Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry 169, 444-450.
27. Kennedy E., Song F., Hunter R., Clark A. & Gilbody S. (1998) Rispiridone versus typical antipsychotic medication for schizophrenia (Cochrane review). In The Cochrane Library, Issue 1, 1999. Update Software, Oxford.
28. Lacy R. (1996) The Complete Guide to Psychiatric Drugs: A Laymans Guide to Antidepressants, Tranquillisers, and Other Prescription Drugs. Vermillion Press, London.
29. Lieberman J.A., Kane J.M., Sarantakos S. et al. (1987) Prediction of relapse in schizophrenia. Archives of Psychiatry 44(7), 597-603.
30. Livingston M. (1994) Antipsychotics:efficacy, side-effects and use. Prescriber 19, 33-51.
31. MacMillan F., Birchwood M. & Smith J. (1992) Predicting and controlling relapses in schizophrenia: early signs monitoring. In Schizophrenia: An Overview and Practical Handbook (Kavinagh DJ. ed.), Chapman and Hall, London, pp 295-307.
32. Marder S.R., Van Putten T., Mintz J. et al. (1984) Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry 41, 1025-1029.
33. Marland G. & McSherry W. (1998) Screening for neuroleptic side-effects. Nursing Times 94(12), 54-55.
34. Marland G. (1998) Partnership encourages patients to comply with treatment. Nursing Times 94(27), 58-59.
35. Marland G. (1999) Atypical neuroleptics: autonomy and compliance? Journal of Advanced Nursing 29(30), 615-622.
36. McCandless-Glincher L., McKnight S., Hamera E. et al. (1986) Use of symptoms by schizophrenics to monitor and regulate their illness. Hospital and Community Psychiatry 37, 929-933.
37. Michaels R.A. & Mumford K. (1989) Identifying akinesia and akathesia: the relationship between patients' self-reports and nurses' assessment. Archives of Psychiatric Nursing 111(2), 97.
38. Mullen P.D., Green L.W. & Persinger G.S. (1985) Clinical trials of patient education for chronic conditions: a comparative meta-analysis of intervention types. Preventive Medicine 14, 723-781.
39. National Health Service Executive (1996) Burden of Disease. NHSE, Leeds.
40. Nyatanga B. (1997) Psychosocial theories of non-compliance. Professional Nurse 12(5), 331-334.
41. Philo G., Secker J., Platt S. et al. (1994) The impact of the mass media on public images of mental illness: media content and audience belief. Health Education Journal 53, 271-281.
42. Quitkin F., Rifkin A., Kane J., Ramos-Lorenzi Jr & Klein D.F. (1978) Long acting oral vs injectable antipsychotic drugs in schozophrenia. A one-year double-blind comparison in multiple episode schizophrenics. Archives of General Psychiatry 35, 889-892.
43. Quraishi S. & David A. (1998) Depot haloperidol decanoate for schizophrenia (Cochrane Review). In The Cochrane Library, Issue 1, 1999. Update Software, Oxford.
44. Repper J. & Perkins R. (1998) A tricky act to balance. Nursing Times 94(11), 36-37.
45. Rich D. (1994) Relapse in the major mental disorders. Australian and New Zealand Journal of Mental Health Nursing 3(4), 132-144.
46. Rifkin A., Quitkin F., Rabiner C.J. & Klein D.F. (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. 1. Relapse rates after one year. Archives of General Psychiatry 34, 43-47.
47. Ryan T. (1994) Interpretations of illness and non-compliance with nursing care. British Journal of Nursing 3(4), 163.
48. Schooler N.R., Lerme J. & Severe J.B. (1980) Prevention of relapse in schizophrenia. Archives of General Psychiatry 37(1), 16-24.
49. Schooler N.R. (1986) The efficacy of antipsychotic drugs, and family therapies and the maintainance treatment of schizophrenia. Journal of Clinical Psychopharmacology 6, 115-195.
50. Seltzer A., Roncari I. & Garfinkel P. (1980) Effect of patient education on medication compliance. Canadian Journal of Psychiatry 25, 638-645.
51. Skidmore D. (1994) The Ideology of Community Care. Chapman & Hall, London.
52. Speller J., Barnes D., Curson C., Pantelis C. & Alberts J. (1997) One year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. British Journal of Psychiatry 171, 564-568.
53. Stockwell M.L., Schulz R.M. (1992) Patient compliance: an overview. Journal of Clinical Pharmacy and Therapeutics 17, 283-295.
54. th edn. Mosby, London.
55. Swain D.L. & Steckel S.B. (1989) Influencing adherence among hypertensives. Research in Nursing and Health 4, 213-222.
56. Tarrier N., Barrowclough C. & Bamrah J.S. (1991) Prodromal signs of relapse in schizophrenia. Social Psychiatry and Psychiatric Epidemiology 26(4), 157-161.
57. Trostle J.A. (1988) Medical compliance as an ideology. Social Science and Medicine 27, 1299-1308.
58. Turner G. (1993) Client/CPN contact during the administration of depot medications: implications for practice. In Community Psychiatric Nursing. A Research Perspective (Brooker C & White E. eds), Vol. 2, Chapman & Hall, London, pp. 71-100.
59. UKCC (1998) Guidelines for Mental Health and Learning Disabilities Nursing. United Kingdom Central Council for Nursing, Midwifery and Health Visiting, London.
60. UKCC (1922) Standards for the Administration of Medicines. United Kingdom Central Council for Nursing, Midwifery and Health Visiting, London.
61. Usher K. & Arthur D. (1998) Process consent: a model for enhancing informed consent in mental health nursing. Journal of Advanced Nursing 27, 692-697.
62. Weiden P., Rapkin B., Zygmunt A. et al. (1995) Post-discharge medication compliance of inpatients converted from oral to a depot neuroleptic regimen. Psychiatric Service 46(10), 1049-1054.
63. Weil F. (1996) The broadened framework of compulsory interventions in the new Israeli law. Their practical consequences. Medical Law 15(2), 233-239.
64. Woof K., Goldberg D. & Fryers T. (1988) The practice of mental health nursing and social work in Salford: some implications for community care. British Journal of Psychiatry 152, 783-792.